ERBB2 and gastric cancer: The developing standard of care in GC is evaluation of human epidermal growth factor receptor 2 (Her2), mismatch repair (MMR), and programmed cell death ligand 1 (PD-L1) status in tumors, with related targeted therapies informing medical and surgical management and studies for these proteins also being done on preoperative specimens [45, 46].